{"entity":{"id":"nct05463263","kind":"trial","name":"A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas","aka":[],"tldr":"A phase 1/2 trial of STP938 in non-Hodgkin lymphoma, run by Step Pharma, SAS, now recruiting.","summary":"A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas is a phase 1/2 interventional study registered as NCT05463263 by Step Pharma, SAS, with 180 participants planned, started 2022-08-03 and due to reach its primary completion in 2026-12. Interventions recorded: STP938.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05463263","url":"https://clinicaltrials.gov/study/NCT05463263"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05463263","phase":"1/2","setting":"An Open-Label, First in Human, Phase 1/2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas","sponsor":"Step Pharma, SAS","enrolled":180,"outcomes":[]},"route":"/trials/nct05463263/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"stp938","kind":"drug","name":"STP938","route":"/drugs/stp938/"}]}}